The phase III IMmotion010 trial evaluated atezolizumab monotherapy vs placebo as adjuvant therapy in patients with renal cell carcinoma (RCC) who were at increased risk of recurrence after resection. Data from the trial was presented by Bex et al at the European Society for Medical Oncology (ESMO) Congress 2022 (
Abstract LBA6).
